Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Tumori|April 16, 2009
Treatment of multiple relapsing non-melanoma skin cancers in a patient with severe hemophilia ASilva Zupancic Salek, Ivo Radman, Drazen Pulanic, et al.
Collegium Antropologicum|September 13, 2007
Erdheim-Chester disease and concomitant tuberculosis successfully treated with chemotherapy and long-term steroidsSasa Badzek, Ana Misir-Krpan, Zdenko Krajina, et al.
Clinical Lymphoma & Myeloma|January 12, 2008
Successful treatment of diffuse large B-cell non-hodgkin lymphoma with modified CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy and rituximab in a patient with Nijmegen syndromeMiroslav Dumic, Ivo Radman, Nevena Krnic, et al.
Pathology Oncology Research : POR|September 21, 2010
Prognostic significance of survivin and caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOPZdravko Mitrović, Ivana Ilić, Igor Aurer, et al.
Radiation Oncology (London, England)|June 22, 2013
Radiotherapy of primary cutaneous follicle center lymphoma: case report and review of literatureRomana Ceovic, Ivana Jovanovic, Kresimir Kostovic, et al.
Onkologie|October 27, 2005
Gemcitabine in the treatment of relapsed and refractory Hodgkin's diseaseIgor Aurer, Ivo Radman, Damir Nemet, et al.
Clinical Lymphoma & Myeloma|May 2, 2009
CD43 expression is an adverse prognostic factor in diffuse large B-Cell lymphomaZdravko Mitrovic, Ivana Ilic, Marin Nola, et al.
International Journal of Hematology|June 5, 2009
Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximabIvana Ilić, Zdravko Mitrović, Igor Aurer, et al.
Collegium Antropologicum|May 4, 2010
FNA based diagnosis of head and neck nodal lymphomaKoraljka Gjadrov Kuvezdić, Igor Aurer, Suncica Ries, et al.
Lijecnicki Vjesnik|November 8, 2006
[90Y-ibritumomab tiuxetan in patients with follicular lymphoma relapsing or refractory to rituximab]Igor Aurer, Drazen Huić, Marijan Zuvić, et al.
Pageof 4